Cholesterol and breast cancer pathophysiology

Trends in Endocrinology and Metabolism

Volumn 25, Issue 12, 2014, Pages 649-655

  Nelson, Erik R ^a   Chang, Ching yi ^b   McDonnell, Donald P ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

26 HYDROXYCHOLESTEROL; CHOLESTEROL; ESTROGEN; LIVER X RECEPTOR; OXYSTEROL; 27-HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE; ESTROGEN RECEPTOR; ORPHAN NUCLEAR RECEPTOR;

AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RISK; DYSLIPIDEMIA; HUMAN; METASTASIS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; BREAST TUMOR; FEMALE; METABOLISM;

BREAST NEOPLASMS; CHOLESTEROL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, ESTROGEN;

EID: 84922946532     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2014.10.001     Document Type: Review

References (64)

1. American Cancer Society Breast Cancer Facts and Figures 2011-2012 2011, American Cancer Society.
2. Shah R., et al. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J. Clin. Oncol. 2014, 5:283-298.
3. Petracci E., et al. Risk factor modification and projections of absolute breast cancer risk. J. Natl. Cancer Inst. 2011, 103:1037-1048.
4. Bianchini F., et al. Overweight, obesity, and cancer risk. Lancet Oncol. 2002, 3:565-574.
5. Capasso I., et al. Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience. Cancer Biol. Ther. 2011, 10:1240-1243.
6. Renehan A.G., et al. Obesity and cancer: pathophysiological and biological mechanisms. Arch. Physiol. Biochem. 2008, 114:71-83.
7. Must A., et al. The disease burden associated with overweight and obesity. JAMA 1999, 282:1523-1529.
8. Howard B.V., et al. Obesity and dyslipidemia. Endocrinol. Metab. Clin. North Am. 2003, 32:855-867.
9. Centers fo Disease Control and Prevention Prevalence of abnormal lipid levels among youths - United States, 1999-2006. MMWR 2010, 59:29-33.
10. Gostynski M., et al. Analysis of the relationship between total cholesterol, age, body mass index among males and females in the WHO MONICA Project. Int. J. Obes. Relat. Metab. Disord. 2004, 28:1082-1090.
11. White C.P. On the occurrence of crystals in tumors. J. Pathol. Bacteriol. 1909, 13:3-10.
12. Danilo C., Frank P.G. Cholesterol and breast cancer development. Curr. Opin. Pharmacol. 2012, 12:677-682.
13. Laisupasin P., et al. Comparison of serum lipid profiles between normal controls and breast cancer patients. J. Lab. Physicians 2013, 5:38-41.
14. Hu J., et al. Dietary cholesterol intake and cancer. Ann. Oncol. 2012, 23:491-500.
15. Ronco A.L., et al. Hormonal and metabolic modulation through nutrition: towards a primary prevention of breast cancer. Breast 2010, 19:322-332.
16. Kitahara C.M., et al. Total cholesterol and cancer risk in a large prospective study in Korea. J. Clin. Oncol. 2011, 29:1592-1598.
17. de Boussac H., et al. LXR, prostate cancer and cholesterol: the good, the bad and the ugly. Am. J. Cancer Res. 2013, 3:58-69.
18. Gazzerro P., et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol. Rev. 2012, 64:102-146.
19. Undela K., et al. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res. Treat. 2012, 135:261-269.
20. Ahern T.P., et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl. Cancer Inst. 2011, 103:1461-1468.
21. Kwan M.L., et al. Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res. Treat. 2008, 109:573-579.
22. Nielsen S.F., et al. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 2012, 367:1792-1802.
23. Ahern T.P., et al. Statins and breast cancer prognosis: evidence and opportunities. Lancet Oncol. 2014, 15:e461-e468.
24. Waxler S.H., et al. Obesity and the time of appearance of spontaneous mammary carcinoma in C3H mice. Cancer Res. 1953, 13:276-278.
25. Llaverias G., et al. Role of cholesterol in the development and progression of breast cancer. Am. J. Pathol. 2011, 178:402-412.
26. Maglione J.E., et al. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res. 2001, 61:8298-8305.
27. Pfefferle A.D., et al. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013, 14:R125.
28. Alikhani N., et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene 2013, 32:961-967.
29. Liu J., et al. Cholesterol-induced mammary tumorigenesis is enhanced by adiponectin deficiency: role of LDL receptor upregulation. Oncotarget 2013, 4:1804-1818.
30. Nelson E.R., et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science 2013, 342:1094-1098.
31. Sullivan P.M., et al. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J. Biol. Chem. 1997, 272:17972-17980.
32. Pelton K., et al. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am. J. Pathol. 2014, 184:2099-2110.
33. Das A., et al. Three pools of plasma membrane cholesterol and their relation to cholesterol homeostasis. eLife 2014, e02882.
34. Hua X., et al. Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics 1995, 25:667-673.
35. Cheskis B.J., et al. Signaling by estrogens. J. Cell. Physiol. 2007, 213:610-617.
36. Radhakrishnan A., et al. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6511-6518.
37. Szanto A., et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol. Cell. Biol. 2004, 24:8154-8166.
38. Zelcer N., et al. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
39. Zhang L., et al. Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:2541-2546.
40. Bensinger S.J., et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
41. Pommier A.J., et al. Liver x receptors protect from development of prostatic intra-epithelial neoplasia in mice. PLoS Genet. 2013, 9:e1003483.
42. DuSell C.D., et al. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 2008, 22:65-77.
43. Umetani M., et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 2007, 13:1185-1192.
44. DuSell C.D., et al. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 2010, 151:3675-3685.
45. Nelson E.R., et al. The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver x receptors. Endocrinology 2011, 152:4691-4705.
46. Umetani M., et al. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha. Cell Metab. 2014, 20:172-182.
47. Karuna R., et al. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. Atherosclerosis 2011, 214:448-455.
48. Fu X., et al. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 2001, 276:38378-38387.
49. Song C., Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor alpha. Endocrinology 2000, 141:4180-4184.
50. Corsini A., et al. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 1995, 31:9-27.
51. Pencheva N., et al. Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation. Cell 2014, 156:986-1001.
52. Vedin L.L., et al. The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis 2009, 30:575-579.
53. Zhang W., et al. Liver X receptor activation induces apoptosis of melanoma cell through caspase pathway. Cancer Cell Int. 2014, 14:16.
54. Cruz P., et al. Proliferation of human mammary cancer cells exposed to 27-hydroxycholesterol. Exp. Ther. Med. 2010, 1:531-536.
55. Wu Q., et al. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. Cell Rep. 2013, 5:637-645.
56. Nachtergaele S., et al. Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat. Chem. Biol. 2012, 8:211-220.
57. Villablanca E.J., et al. Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat. Med. 2010, 16:98-105.
58. Hansson M., et al. Marked induction of sterol 27-hydroxylase activity and mRNA levels during differentiation of human cultured monocytes into macrophages. Biochim. Biophys. Acta 2003, 1593:283-289.
59. Sica A., et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
60. Bahl M., et al. Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study. Breast Cancer Res. Treat. 2005, 94:135-144.
61. Jiralerspong S., et al. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann. Oncol. 2013, 24:2506-2514.
62. Raccosta L., et al. The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils. J. Exp. Med. 2013, 210:1711-1728.
63. Lappano R., et al. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. PLoS ONE 2011, 6:e16631.
64. Thelen K.M., et al. Effect of pravastatin on plasma sterols and oxysterols in men. Eur. J. Clin. Pharmacol. 2006, 62:9-14.